Navigation Links
Hydrocodone and Oxycodones Lead U.S. General Workforce Positives, Outranked Only by Marijuana, According to Quest Diagnostics Drug Testing Index™
Date:10/11/2011

MADISON, N.J., Oct. 11, 2011 /PRNewswire/ -- American workers continue to use prescription opiates at relatively high levels, according to Drug Testing Index™ (DTI) data released today by Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services. Hydrocodone and oxycodones remain the most detected prescription opiates in the U.S. general workforce, with 1.3% and 1.1% positivity rates, respectively, in the first half of 2011. Compared to 2005 levels, oxycodones are 96% higher (0.56% vs. 1.1%) and hydrocodone 47% higher (0.88% vs. 1.3%) in positive prevalence.

According to Drug Testing Index data from urine drug tests, only marijuana, at 2.0% in the first half of 2011, holds a positivity rate higher than hydrocodone (1.3%) and oxycodones (1.1%). This ranking is consistent with 2010 National Survey on Drug Use and Health self-reported survey findings recently released by the U.S. Substance Abuse and Mental Health Services Administration, showing marijuana as the top drug associated with initiation of illicit drug use and pain relievers as second in ranking.

"The use and misuse of prescription opiates continue to capture national attention," said Dr. Barry Sample, Quest Diagnostics Director of Science and Technology for Employer Solutions. "The findings of this study reinforce the need for businesses to develop and communicate clear policies around both the medical and non-medical use of these drugs, especially for their safety-sensitive workers. Empowering employees to perform duties safely, act appropriately when they perceive risk, and understand clearly the consequences of non-medical use of these drugs and of being found to have violated their employer's drug policy all play an important role in worker and public safety."

Random drug testing and post-accident testing detected dramatically more positives for prescription opiates than pre-employment drug testing from January 2011 through June 2011 in the U.S. general workforce. Pre-employment screening revealed a 0.85% positivity rate for hydrocodone and a 0.65% positivity rate for oxycodones. However, random drug test positivity was nearly double, at 1.6% and 1.2%, respectively. Post-accident testing for hydrocodone and oxycodones continue to reveal dramatically higher rates of positivity at 3.7% and 1.8%, respectively.

"Prescription opiates are effective for managing pain and have been shown to improve patients' quality of life," said Jon R. Cohen, M.D., Quest Diagnostics Senior Vice President and Chief Medical Officer. "However, when used outside of a prescription and without the guidance of a physician, these powerful and highly addictive drugs can present serious health dangers to those who misuse them, and serious risks to workplace and public safety."

Recent government efforts to address the national epidemic of non-medical use of prescription drugs include the recent U.S. Drug Enforcement Agency's (DEA) "take-back" initiative in April, which collected more than 188 tons of prescription medications nationwide, and the upcoming National Prescription Drug Take Back Day scheduled to take place later this month on October 29th.

For more information on the Quest Diagnostics Drug Testing Index, visit www.QuestDiagnostics.com/DTI.

About Quest Diagnostics Quest Diagnostics is the world's leading provider of diagnostic testing, information and services that patients and doctors need to make better healthcare decisions. The company offers the broadest access to diagnostic testing services through its network of laboratories and patient service centers, and provides interpretive consultation through its extensive medical and scientific staff. Quest Diagnostics is a pioneer in developing innovative new diagnostic tests and advanced healthcare information technology solutions that help improve patient care. Additional company information is available at: http://www.QuestDiagnostics.com.

Tables FollowPercent Testing Positive for "Expanded Opiates" – Urine Drug Tests(For General U.S. Workforce, as a percentage of all tests for "Expanded Opiates")

(More than 270 thousand tests from January 2011 to June 2011)200520062007200820092010Jan – Jun
2011Codeine

0.22%

0.20%

0.19%

0.20%

0.21%

0.17%

0.20%Morphine

0.45%

0.37%

0.43%

0.43%

0.48%

0.42%

0.42%Hydrocodone

.88%

.97%

1.2%

1.1%

1.3%

1.3%

1.3%Hydromorphone

.47%

.54%

0.74%

0.73%

0.82%

0.71%

0.70%Percent Testing Positive for Oxycodones (Oxycodone and/or Oxymorphone) – Urine Drug Tests(For General U.S. Workforce, as a percentage of all tests for Oxycodones)

(More than 280 thousand tests from January 2011 to June 2011)200520062007200820092010Jan – Jun
2011Oxycodones

0.56%

0.64%

0.88%

0.83%

1.0%

1.0%

1.1%Percent Testing Positive for Marijuana – Urine Drug Tests
(For General U.S. Workforce, as a percentage of all such tests)
(More than 2.4 million tests from January to June 2011)200520062007200820092010Jan – Jun

2011Marijuana

2.5%

2.4%

2.3%

2.1%

2.0%

2.0%

2.0%For more information on the Quest Diagnostics Drug Testing Index, visit www.QuestDiagnostics.com/DTI.

The Drug Testing Index © 2011 Quest Diagnostics Incorporated. All rights reserved.

Contacts:
Media: Barb Short, 973-520-2800
Investors: Kathleen Valentine, 973-520-2900


'/>"/>

SOURCE Quest Diagnostics Incorporated
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Ranbaxy Receives Approval to Manufacture and Market Hydrocodone Bitartrate and Acetaminophen Tablets USP
2. Abbott Receives Complete Response Letter From FDA for Controlled-Release Hydrocodone With Acetaminophen
3. Zogenix Initiates Pivotal Phase 3 Clinical Trial for Novel Formulation of Oral Controlled-Release Hydrocodone
4. Abuse Deterrent Hydrocodone / Acetaminophen Leads NDA Pipeline
5. Boca Pharmacal Receives FDA Approval for Hydrocodone Bitartrate and Acetaminophen Tablets
6. Qualitest Pharmaceuticals Issues Voluntary, Nationwide Recall of Hydrocodone Bitartrate and Acetaminophen Tablets, USP 10 mg / 500 mg, NDC 0603-3888-20, 60 Count, Lot Numbers T150G10B, T120J10E and T023M10A and Phenobarbital Tablets, USP 32.4 mg, ND
7. General Wesley Clark Joins Immtech as Consulting Strategic Advisor
8. Neupro(R) (Rotigotine Transdermal System) Effective in Controlling Early Morning Motor Impairment and Generally Well-Tolerated for Long-Term Use in Patients with Parkinsons Disease
9. Sugammadex Trials Demonstrate Rapid Recovery from Profound Neuromuscular Blockade During General Anesthesia
10. Ethics Group Asks USAID Inspector General to Investigate Legality of Grants to Soros Groups
11. Allegheny General Hospital Performs First Liver Transplant
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/15/2017)... , Aug. 15, 2017  Axium Pharmaceuticals Inc., the creator of ... to be in the beginning stages of an IPO. ... epilepsy medications with the average cost of a prescription epilepsy drug being ... AXIUM ... Another staggering figure is the fact that ...
(Date:8/14/2017)... N.J. and PETACH TIKVAH, Israel ... Inc. (NASDAQ: BCLI), a leading developer of adult stem ... the second quarter ending June 30, 2017. ... stages of preparing for our pivotal Phase 3 trial ... Chaim Lebovits , President and Chief Executive Officer of ...
(Date:8/8/2017)... 2017  BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical ... financial results for the second quarter ended June 30, ... quarter 2017 and to date: ... for the Company,s lead project, BL-8040: ... BL-8040 as novel stem cell mobilization treatment for autologous ...
Breaking Medicine Technology:
(Date:8/21/2017)... ... , ... PracticeMatch, a company that provides online resources , job ... practitioners like nurse practitioners and physician assistants , will conduct its ... year. The online career fairs will allow job seekers to connect with healthcare employers ...
(Date:8/21/2017)... ... August 21, 2017 , ... Los Angeles area ... fellows for academic year 2017-2018, Christina M. Busuito, M.D. and Lukasz Swistun, M.D. ... in Plastic and Reconstructive Surgery. The candidate will have the opportunity to ...
(Date:8/21/2017)... ... August 21, 2017 , ... Five chefs from local senior ... Alzheimer’s Family Center. , Guests will be able to vote for their favorite ... Lamb Shank with Fennel Dill Salad, Feta Cheese Sauce & Garlic Pita Crisp, Greek ...
(Date:8/21/2017)... , ... August 21, 2017 , ... The experts have ... are we supposed to get things done in a healthy way these days? FlexiSpot, ... launching a crowdfunding campaign on August 28 to introduce Deskcise Pro™– the world’s first ...
(Date:8/21/2017)... ... August 21, 2017 , ... San Diego physician and surgeon ... reform plan, has announced his candidacy for the 52nd Congressional District currently held by ... America’s Promise. Coming to this country at age eleven after suffering homelessness and hardship ...
Breaking Medicine News(10 mins):